<DOC>
	<DOCNO>NCT01371747</DOCNO>
	<brief_summary>This study determine optimal start dose patiromer treat hyperkalemia participant hypertension diabetic nephropathy already receive ACEI and/or ARB drug , without spironolactone . This study also evaluate efficacy safety patiromer long term use patiromer .</brief_summary>
	<brief_title>Patiromer Treatment Hyperkalemia Patients With Hypertension Diabetic Nephropathy ( AMETHYST-DN )</brief_title>
	<detailed_description>RLY5016-205 open-label , randomize , dose range study determine optimal start dose , efficacy safety patiromer treat hyperkalemia hypertensive patient nephropathy due type 2 diabetes mellitus ( T2DM ) already receive Angiotensin-converting Enzyme Inhibitor ( ACEI ) and/or Angiotensin II Receptor Blocker ( ARB ) drug , without spironolactone . The study consist follow period : - Screening : Up 10 day ( 1 visit ) - Run-in hyperkalemic screening ( Cohorts 1 2 ) : 4 week ( 1 4 visit ) - Patiromer Treatment Initiation : first 8 week patiromer treatment ( minimum 10 visit ) - Patiromer Long-Term Maintenance : additional 44 week patiromer treatment total one year ( minimum 11 additional visit ) - Follow-up ( patiromer discontinuation ) : 1 week ( 2 visit ) OR 4 week ( 5 visit ) depend final serum potassium level</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Hyperkalemia</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<criteria>1 . Age 30 80 year old screening ( S1 ) 2 . Type 2 diabetes mellitus ( T2DM ) diagnose age 30 treated oral medication insulin least 1 year prior S1 3 . Chronic kidney disease ( CKD ) : estimate glomerular filtration rate ( eGFR ) 15 &lt; 60 mL/min/1.73m2 screen base central lab serum creatinine measurement ( except participant hyperkalemia S1 ) , whose eligibility assess base local lab eGFR value ) 4 . Urine albumin/creatinine ratio ( ACR ) : 1 . Cohorts 1 2 : urine ACR ≥ 30 mg/g S1 AND average urine ACR ≥ 30 mg/g begin RunIn Period ( R0 ) base three ACR value obtain start S1 end R0 Visit 2 . Cohort 3 : applicable 5 . Local laboratory serum potassium ( K+ ) value : 1 . Cohorts 1 2 : 4.3 5.0 mEq/L S1 ; AND 4.5 5.0 mEq/L R0 ; AND &gt; 5.0 &lt; 6.0 mEq/L randomization patiromer ( Baseline , T0 Visit ) 2 . Cohort 3 : &gt; 5.0 &lt; 6.0 mEq/L S1 OR R0 day confirmation 6 . Must receive ACEI and/or ARB least 28 day prior screen 7 . Average systolic blood pressure ( SBP ) ≥ 130 &lt; 180 mmHg AND average DBP ≥ 80 &lt; 110 mmHg ( sit ) screen R0 ( applicable ) 8 . Females childbearing potential must nonlactating , must negative serum pregnancy test screening , must use highly effective form contraception least 3 month patiromer administration , study , one month study completion 9 . Provide write informed consent prior participation study 1 . Type 1 diabetes mellitus 2 . Central lab hemoglobin A1c &gt; 12 % Screening 1 ( S1 ) ( except Cohort 3 participant hyperkalemic S1 ) 3 . Emergency treatment T2DM within last 3 month 4 . A confirmed SBP &gt; 180 mmHg diastolic blood pressure ( DBP ) &gt; 110 mmHg time SI RunIn Period Baseline T0 Visit 5 . Central lab serum magnesium &lt; 1.4 mg/dL ( &lt; 0.58 mmol/L ) screening ( Cohort 3 participant evaluate base local lab serum magnesium measurement ) 6 . Central lab urine ACR ≥ 10000 mg/g screening ( except Cohort 3 participant hyperkalemic S1 ) 7 . Confirmed diagnosis history renal artery stenosis ( unilateral bilateral ) 8 . Diabetic gastroparesis 9 . Nondiabetic chronic kidney disease 10 . History bowel obstruction , swallow disorder , severe gastrointestinal disorder major gastrointestinal surgery ( e.g. , large bowel resection ) 11 . Current diagnosis NYHA ( New York Heart Association ) Class III IV heart failure 12 . Body mass index ( BMI ) ≥ 40 kg/m2 13 . Any following event occur within 2 month prior screen : unstable angina judge Principal Investigator ( PI ) , unresolved acute coronary syndrome , cardiac arrest clinically significant ventricular arrhythmia , transient ischemic attack stroke , use intravenous cardiac medication 14 . Prior kidney transplant , anticipate need transplant study participation 15 . Active cancer , currently cancer treatment history cancer past 2 year except nonmelanocytic skin cancer consider cure 16 . History alcoholism drug/chemical abuse within 1 year 17 . Central lab liver enzymes [ alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) ] &gt; 3 time upper limit normal S1 ( except Cohort 3 patient hyperkalemia S1 , local lab ALT AST ) 18 . Loop thiazide diuretic antihypertensive medication ( calcium channel blocker , betablocker , alphablocker , centrally act agent ) stable least 28 day prior screen anticipate remain stable study participation 19 . Current use polymerbased drug ( e.g. , sevelamer , sodium polystyrene sulfonate , colesevelam , colestipol , cholestyramine ) , phosphate binder ( e.g. , lanthanum carbonate ) , potassium binder , anticipate need study participation 20 . Current use lithium 21 . Use potassium spar medication , include aldosterone antagonist ( e.g. , spironolactone ) , drospirenone , potassium supplement , bicarbonate baking soda last 7 day prior screen 22 . Use investigational product within 30 day 5 halflives , whichever longer , prior screen 23 . Inability consume investigational product , , opinion Investigator , inability comply protocol 24 . In opinion Investigator , medical condition , uncontrolled systemic disease , serious intercurrent illness would significantly decrease study compliance jeopardize safety participant affect validity trial result</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Hyperkalemia</keyword>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>Treatment Hyperkalemia</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Diabetic Nephropathy</keyword>
</DOC>